Determining the extent and stage of disease in patients with
newly diagnosed non-Hodgkin’s lymphoma using 18F-FDG-PET/CT

J 2011

Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin’s lymphoma using 18F-FDG-PET/CT

PAPAJÍK, Tomáš; Miroslav MYSLIVEČEK; M. SKOPALOVÁ; A. MALAN; Eva BURIÁNKOVÁ et al.

Základní údaje

Originální název

Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin’s lymphoma using 18F-FDG-PET/CT

Autoři

Vydání

Neoplasma, 2011, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.440

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/11:00052521

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.4149/neo_2011_04_291

UT WoS

000290695900003

Klíčová slova anglicky

18F-FDG PET; PET/CT; CT; non-Hodgkins lymphoma staging

Příznaky

Mezinárodní význam

Změněno: 12. 4. 2012 08:12, Mgr. Michal Petr

Anotace

V originále

Positron emission tomography (PET) using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (18F-FDG) combined with computed tomography (CT) represents a three-dimensional imaging method suitable for staging in patients with non-Hodgkin’s lymphomas (NHLs). The aim of our prospective multicenter study was to assess the value of initial PET/CT as compared with CT and PET alone for determining the stage and extent of the disease. A total of 122 patients with newly diagnosed NHL were examined using PET/CT. Four patients with resected lymphoma lesion and negative PET/CT were therefore excluded from the study. Of the remaining 118 cases, a total of 117 (99%) were described as 18F-FDG-avid. When compared with PET/CT, CT and PET showed very good sensitivity of lymph node imaging (97% and 100%, respectively); the specificity, however, was significantly lower (66.7% and 94.4%, respectively; p=0.0001). When detecting organ lesions, the sensitivity of CT and PET was lower than that of PET/CT (92.5% and 96.3%, respectively; p=0.0001); specificity was significantly decreased in CT and a little lower in PET (59.5% and 91.9%; p=0.0001). When compared with CT alone, PET/CT changed staging of the disease in 11 patients (9%) and was able to detect a total of 82 discrepancies in 67 of the 117 patients (57%). In conclusion, PET/CT is a new standard in imaging the involvement of lymph nodes and extranodal organs in NHL patients regardless of their histopathological types. Both sensitivity and specificity of the examination are higher than those of CT as well as PET alone.

Citovat

PAPAJÍK, Tomáš; Miroslav MYSLIVEČEK; M. SKOPALOVÁ; A. MALAN; Eva BURIÁNKOVÁ; V. KOZA; M. HNÁTKOVÁ; M. TRNĚNÝ; Zuzana ŠEDOVÁ; Zuzana KUBOVÁ; Pavel KORANDA; Patrik FLODR; Jiří JARKOVSKÝ; Ladislav DUŠEK a Karel INDRÁK. Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin’s lymphoma using 18F-FDG-PET/CT. Neoplasma. 2011, roč. 58, č. 4, s. 291-297. ISSN 0028-2685. Dostupné z: https://doi.org/10.4149/neo_2011_04_291.

@article{942696,
   author = {Papajík, Tomáš and Mysliveček, Miroslav and Skopalová, M. and Malan, A. and Buriánková, Eva and Koza, V. and Hnátková, M. and Trněný, M. and Šedová, Zuzana and Kubová, Zuzana and Koranda, Pavel and Flodr, Patrik and Jarkovský, Jiří and Dušek, Ladislav and Indrák, Karel},
   article_number = {4},
   doi = {https://doi.org/10.4149/neo_2011_04_291},
   keywords = {18F-FDG PET; PET/CT; CT; non-Hodgkins lymphoma staging},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin’s lymphoma using 18F-FDG-PET/CT},
   volume = {58},
   year = {2011}
}

TY  - JOUR
ID  - 942696
AU  - Papajík, Tomáš - Mysliveček, Miroslav - Skopalová, M. - Malan, A. - Buriánková, Eva - Koza, V. - Hnátková, M. - Trněný, M. - Šedová, Zuzana - Kubová, Zuzana - Koranda, Pavel - Flodr, Patrik - Jarkovský, Jiří - Dušek, Ladislav - Indrák, Karel
PY  - 2011
TI  - Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin’s lymphoma using 18F-FDG-PET/CT
JF  - Neoplasma
VL  - 58
IS  - 4
SP  - 291-297
EP  - 291-297
SN  - 00282685
KW  - 18F-FDG PET
KW  - PET/CT
KW  - CT
KW  - non-Hodgkins lymphoma staging
N2  - Positron emission tomography (PET) using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (18F-FDG) combined with computed tomography (CT) represents a three-dimensional imaging method suitable for staging in patients with non-Hodgkin’s lymphomas (NHLs). The aim of our prospective multicenter study was to assess the value of initial PET/CT as compared with CT and PET alone for determining the stage and extent of the disease. A total of 122 patients with newly diagnosed NHL were examined using PET/CT. Four patients with resected lymphoma lesion and negative PET/CT were therefore excluded from the study. Of the remaining 118 cases, a total of 117 (99%) were described as 18F-FDG-avid. When compared with PET/CT, CT and PET showed very good sensitivity of lymph node imaging (97% and 100%, respectively); the specificity, however, was significantly lower (66.7% and 94.4%, respectively; p=0.0001). When detecting organ lesions, the sensitivity of CT and PET was lower than that of PET/CT (92.5% and 96.3%, respectively; p=0.0001); specificity was significantly decreased in CT and a little lower in PET (59.5% and 91.9%; p=0.0001). When compared with CT alone, PET/CT changed staging of the disease in 11 patients (9%) and was able to detect a total of 82 discrepancies in 67 of the 117 patients (57%). In conclusion, PET/CT is a new standard in imaging the involvement of lymph nodes and extranodal organs in NHL patients regardless of their histopathological types. Both sensitivity and specificity of the examination are higher than those of CT as well as PET alone.
ER  -

PAPAJÍK, Tomáš; Miroslav MYSLIVEČEK; M. SKOPALOVÁ; A. MALAN; Eva BURIÁNKOVÁ; V. KOZA; M. HNÁTKOVÁ; M. TRNĚNÝ; Zuzana ŠEDOVÁ; Zuzana KUBOVÁ; Pavel KORANDA; Patrik FLODR; Jiří JARKOVSKÝ; Ladislav DUŠEK a Karel INDRÁK. Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin’s lymphoma using 18F-FDG-PET/CT. \textit{Neoplasma}. 2011, roč.~58, č.~4, s.~291-297. ISSN~0028-2685. Dostupné z: https://doi.org/10.4149/neo\_{}2011\_{}04\_{}291.

Přehled o publikaci